2026-04-29T04:52:19Zhttps://repisalud.isciii.es/rest/oai/request

oai:repisalud.isciii.es:20.500.12105/268292025-12-18T12:57:26Zcom_20.500.12105_19586com_20.500.12105_2202col_20.500.12105_19587

00925njm 22002777a 4500 dc Felgueres, María-José author Esteso, Gloria author García-Jiménez, Álvaro F author Benguría, Alberto author Vázquez, Enrique author Aguiló, Nacho author Puentes, Eugenia author Dopazo, Ana author Murillo, Ingrid author Martín, Carlos author Rodríguez, Esteban author Reyburn, Hugh T author Valés-Gómez, Mar author 2025-03-28 Infection with Mycobacterium tuberculosis (Mtb) can produce a wide spectrum of clinical manifestations, ranging from active tuberculosis (TB) to asymptomatic latent infection. Although CD4 T-cells are key immune effectors to control TB, early after infection, the innate immune response must play a role in tackling the disease. Here, we performed in-depth analyses of the acute immune response to MTBVAC, a candidate vaccine engineered from Mtb with the aim of protecting adults from pulmonary TB disease, still a major global challenge. scRNA-seq shows expansion of CD4 and cytotoxic γδ T-cells, data confirmed by flow cytometry. CD4 T-cells exhibited lower HLA-DR and higher L-selectin expression, compared to BCG-stimulation, indicating differential activation or dynamics. Importantly, MTBVAC-activated γδ T-cells had a unique cytotoxic CD16GZMB phenotype, reminiscent of effector cells found in Mtb positive individuals controlling infection. IFN-γ and TNF-α were released in cultures, while IL-17A/F were almost undetectable. NPJ Vaccines. 2025 Mar 28;10(1):58. https://hdl.handle.net/20.500.12105/26829 40155627 NPJ Vaccines Cytolytic γδ T-cells and IFNγ-producing CD4-lymphocytes characterise the early response to MTBVAC tuberculosis vaccine.